EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Switching PD‐1 to BRAF + MEK inhibition improves recurrence‐free survival in patients receiving a second course of adjuvant melanoma therapy

Katharina Schumann iD, Kai Christian Klespe, Cornelia Mauch, Carmen Loquai, Ulrike Schultheis, Sevil Börger, Alexander Thiem iD, Steffen Emmert, Magdalena Hoellwerth, Peter Kölblinger, Van Anh Nguyen, Marina Wanner und 14 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20708 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Katharina Schumann und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors, Melanoma, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PD‐1 or BRAF + MEK inhibition is considered the current gold standard in adjuvant melanoma therapy. Little is known if, after the recurrence of the disease and surgery, a second course of adjuvant therapy might be beneficial.

Methods

A multicenter, retrospective study investigating a second course of adjuvant therapy after recurrence and surgery in stage III–IV melanoma patients. Patients received nivolumab (NIV), pembrolizumab (PEM) or dabrafenib plus trametinib (D + T) between 01/2017 and 10/2021. The primary endpoint was 12‐month recurrence‐free survival (RFS2). Further analyses included descriptive and correlative statistics.

Results

Sixty‐six patients from 22 centers in Germany, Austria and Switzerland were included. Thirty‐two patients received D + T as second‐course adjuvant therapy, 9 patients received PEM and 25 patients received NIV. Recurrence‐free survival for the second‐course adjuvant treatment (RFS2) was assessed after 12 and 24 months and showed a superiority of adjuvant BRAF + MEK over PD‐1 therapy (12‐months RFS2: 90.6% vs. 70.6%, HR 4.226 [95% CI 1.154–15.48]; p = 0.030; 24‐months RFS2 71.9% vs. 52.9%, HR 3.154 [95% CI 1.374–7.242]; p = 0.007). There was no significant decrease in OS with either BRAF + MEK or PD‐1 treatment (12‐months OS: 100% both, 24‐months OS: 100% vs. 93.8%). Furthermore, therapy sequences were investigated. For better comparability, only BRAF V600 mutated patients were assessed: RFS2 was significantly better for patients with a class switch from PD‐1 to BRAF + MEK compared to BRAF + MEK to PD‐1 (HR 4.401 (1.04–18.63), p = 0.044). No new safety signals were detected.

Conclusions

In the investigated cohort, a second course of adjuvant melanoma treatment is feasible and provides similar RFS compared to an initial course of adjuvant therapy using BRAF + MEK inhibitors; however, RFS2 is reduced for PD‐1 antibodies. In addition, both treatments were convincing with a 24‐month OS of almost 100%. Switching from adjuvant PD‐1 to BRAF + MEK treatment provided better overall RFS compared to switching from adjuvant BRAF + MEK to PD‐1 treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsMelanomaProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins B-rafSkin NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedChemotherapy, AdjuvantDisease-Free SurvivalNeoplasm Recurrence, LocalNivolumabOximesPyridonesPyrimidinonesRetrospective StudiesImidazoles

Substanzen

Antibodies, Monoclonal, HumanizedBRAF protein, humandabrafenibImmune Checkpoint InhibitorsNivolumabOximesPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Munich, Germany.
  • Department for Phlebology and Venerology, Artemed Hospital, Munich, Germany.
  • Department of Dermatology and Allergology, University Hospital RWTH Aachen, Aachen, Germany.
  • Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany.
  • Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany.
  • Department for Dermatology and Allergology, Clinic Bremen Ost, Bremen, Germany.

ORCID-Profile: Katharina Schumann, Alexander Thiem, Wiebke K Peitsch, Andreas Dominik Braun, Miriam Mengoni, Reinhard Dummer, Lara Valeska Maul, Oana Diana Persa

Zitieren

APA

Schumann, K., Klespe, K. C., Mauch, C., Loquai, C., Schultheis, U., Börger, S., Thiem, A., Emmert, S., Hoellwerth, M., Kölblinger, P., Nguyen, V. A., Wanner, M., Richtig, E., Peitsch, W. K., Harth, W., Zenderowski, V., Braun, A. D., Mengoni, M., Dummer, R., …, & Posch, C. (2025). Switching PD‐1 to BRAF + MEK inhibition improves recurrence‐free survival in patients receiving a second course of adjuvant melanoma therapy. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20708

Vancouver

Schumann K, Klespe KC, Mauch C, Loquai C, Schultheis U, Börger S, et al. Switching PD‐1 to BRAF + MEK inhibition improves recurrence‐free survival in patients receiving a second course of adjuvant melanoma therapy. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20708

BibTeX
@article{Schumann2025,
  author = {Schumann, Katharina and Klespe, Kai Christian and Mauch, Cornelia and Loquai, Carmen and Schultheis, Ulrike and Börger, Sevil and Thiem, Alexander and Emmert, Steffen and Hoellwerth, Magdalena and Kölblinger, Peter and Nguyen, Van Anh and Wanner, Marina and Richtig, Erika and Peitsch, Wiebke K and Harth, Wolfgang and Zenderowski, Veronika and Braun, Andreas Dominik and Mengoni, Miriam and Dummer, Reinhard and Mangana, Johanna and Maul, Lara Valeska and Meiß, Frank and Rappersberger, Klemens and Persa, Oana Diana and Biedermann, Tilo and Posch, Christian},
  title = {Switching PD‐1 to BRAF + MEK inhibition improves recurrence‐free survival in patients receiving a second course of adjuvant melanoma therapy},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20708}
}
Kostenlos starten →